Naproxcinod for the treatment of primary osteoarthritis
Following on from information provided to NICE by the company in April 2018 the appraisal of Osteoarthritis – naproxcinod [ID417] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 417
Referral date 01 November 2010
Topic area
  • Musculoskeletal

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Discontinued. Following on from information provided to NICE by the company in April 2018 the appraisal of Osteoarthritis – naproxcinod [ID417] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
27 May 2011 The Institute has been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for naproxcinod.

Further information

NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual